KRAS inhibitors (KU Leuven’s Centre for Drug Design and Discovery)

N/A

Report date: 2025/03/20 16:07:25
NME

Base Information

Drug NameKRAS inhibitors (KU Leuven’s Centre for Drug Design and Discovery)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKU Leuven’s Centre for Drug Design and Discovery
China Registration ClassN/A

Develop Information

Active CompaniesKU Leuven’s Centre for Drug Design and Discovery
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A